[Origin and development of RUTI, a new therapeutic vaccine against Mycobacterium tuberculosis infection].
This article reviews the pathophysiology of the latent form of Mycobacterium tuberculosis along with its natural history and progression in infected tissues. The proposed hypotheses regarding the relationship between M tuberculosis and the associated immune response, the cause of granuloma necrosis, the tolerance of a certain concentration of the bacillus in host tissues, the constant turnover of cells in the lung, and the effect of chemotherapy form the basis for the design of the therapeutic vaccine RUTI against latent M tuberculosis infection. This vaccine is generated from detoxified M tuberculosis cell fragments that facilitate a balanced T helper (Th) 1/Th2/Th3 response to a wide range of antigens along with intense antibody production. Treatment with RUTI following chemotherapy has been demonstrated to be effective in experimental models in mice and guinea pigs and does not exhibit toxicity.
Cardona
P J
PJ
Unitat de Tuberculosi Experimental, Servei de Microbiologia, Fundació Institut per a la Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Barcelona, Spain. pcardona@ns.hugtip.scs.es
Amat
I
I
D000818:Animals; D006801:Humans; D008081:Liposomes; D009169:Mycobacterium tuberculosis / Q000502:physiology; D014376:Tuberculosis / Q000276:immunology* / Q000628:therapy*; D032581:Tuberculosis Vaccines / Q000627:therapeutic use*
D008081:Liposomes; D032581:Tuberculosis Vaccines